Patents by Inventor Alexei Kirkin
Alexei Kirkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240076616Abstract: Provided is a method for preparation of a composition comprising activated human CD4+ and CD8+ lymphocytes. The method entails use of allogeneic mature dendritic cells as feeder cells added at an early stage in the induction of proliferation and activation of CD4+ and CD8+ T cells. Further provided is a method for treatment of lymphopenia related diseases by infusion of the cells obtained from the present process.Type: ApplicationFiled: January 21, 2022Publication date: March 7, 2024Applicant: Cytovac A/SInventor: Alexei Kirkin
-
Patent number: 10023839Abstract: A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are lymphocytes, especially peripheral blood lymphocytes. The tumor antigens are typically cancer/testis antigens, which may be chemically induced by DNA demethylation. Cancer/testis antigens are expressed in a wide range of tumors, so the composition is able to raise an immune response that is effective against a wide range of tumors, despite the fact that it is derived from normal cells. The composition may be used for preparation of an anti-tumor vaccine for prophylactic or therapeutic use.Type: GrantFiled: January 3, 2008Date of Patent: July 17, 2018Assignee: Cytovac A/SInventors: Alexei Kirkin, Karine Dzhandzhugazyan
-
Publication number: 20180036397Abstract: A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are lymphocytes, especially peripheral blood lymphocytes. The tumor antigens are typically cancer/testis antigens, which may be chemically induced by DNA demethylation. Cancer/testis antigens are expressed in a wide range of tumors, so the composition is able to raise an immune response that is effective against a wide range of tumors, despite the fact that it is derived from normal cells. The composition may be used for preparation of an anti-tumor vaccine for prophylactic or therapeutic use.Type: ApplicationFiled: September 18, 2017Publication date: February 8, 2018Inventors: Alexei Kirkin, Karine Dzhandzhugazyan
-
Patent number: 9771558Abstract: The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.Type: GrantFiled: December 7, 2006Date of Patent: September 26, 2017Assignee: DANDRIT DIOTECH A/SInventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
-
Patent number: 9567567Abstract: The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells.Type: GrantFiled: August 11, 2011Date of Patent: February 14, 2017Assignee: Cytovac A/SInventors: Alexei Kirkin, Karine Djandjougazian, Martin Roland Jensen
-
Publication number: 20130216584Abstract: The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells.Type: ApplicationFiled: August 11, 2011Publication date: August 22, 2013Applicant: Cytovac A/SInventors: Alexei Kirkin, Karine Djandjougazian, Martin Roland Jensen
-
Patent number: 7771998Abstract: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.Type: GrantFiled: November 29, 2002Date of Patent: August 10, 2010Assignee: Dandrit Biotech A/SInventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
-
Patent number: 7723107Abstract: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.Type: GrantFiled: July 29, 2008Date of Patent: May 25, 2010Assignee: Dandrit Biotech A/SInventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
-
Publication number: 20100092498Abstract: A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are lymphocytes, especially peripheral blood lymphocytes. The tumor antigens are typically cancer/testis antigens, which may be chemically induced by DNA demethylation. Cancer/testis antigens are expressed in a wide range of tumors, so the composition is able to raise an immune response that is effective against a wide range of tumors, despite the fact that it is derived from normal cells. The composition may be used for preparation of an anti-tumor vaccine for prophylactic or therapeutic use.Type: ApplicationFiled: January 3, 2008Publication date: April 15, 2010Applicant: Cytovac A/SInventors: Alexei Kirkin, Karine Dzhandzhugazyan
-
Publication number: 20090196856Abstract: The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.Type: ApplicationFiled: December 7, 2006Publication date: August 6, 2009Applicant: DanDrit Biotech A/SInventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen
-
Publication number: 20090029457Abstract: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.Type: ApplicationFiled: July 29, 2008Publication date: January 29, 2009Applicant: DANDRIT BIOTECH A/SInventors: Alexei KIRKIN, Karine Djandjougazian, Jesper Zeuthen
-
Publication number: 20060051324Abstract: The present invention relates to a pharmaceutical composition for inducing an immune response in a human or animal, comprising dendritic cells loaded with at least five cancer/testis antigen and no lineage specific differentiation antigens or substantially no lineage specific differentiation antigens provided from at least one cancer cell line, as well as to isolated cell lines expressing a multiplicity of cancer testis antigens and no differentiation antigens, and to a method of inducing an immune response in a human or animal using the composition of the invention.Type: ApplicationFiled: November 29, 2002Publication date: March 9, 2006Inventors: Alexei Kirkin, Karine Djandjougazian, Jesper Zeuthen